Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2016

View Archived Issues

Genentech initiates phase I trial of GDC-0134 in patients with ALS

Worldwide collaborations to control recent Zika virus outbreaks / News in Context

Researchers identify germline variants associated with melanoma prognosis

FDA approves Athenex's IND application for oradoxel

FDA accepts BLA submission for brodalumab in moderate to severe plaque psoriasis

Ixchelsis reports positive phase IIa results for IX-01 as treatment of premature ejaculation

Domainex and Cresset Discovery Services form alliance

Alkermes begins phase I clinical testing of ALKS-7119

FDA accepts for review cardiovascular outcomes data for Jardiance

Phase IIa study of GLPG-1205 in ulcerative colitis does not meet efficacy endpoints

Steba completes phase III trial of Tookad, submits MAA

Biomarkers linked to metastasis of endometrial and lung tumors

OncoMed unblinds phase II trial of tarextumab following DSMB analysis

Shire resubmits NDA for lifitegrast for dry eye disease

Results from part A of MoveDMD trial of CAT-1004 support progression to part B

WuXi Healthcare Ventures invests in Twist Bioscience and Syros Pharmaceuticals

Pharmaceutical industry calls for government collaboration to fight antibiotic resistance

Polish institutions report 5-HT/dopamine receptor modulators

Moberg Pharma issues a 5-year senior unsecured bond loan

Sunshine Lake Pharma discloses JAK3 inhibitors

Novartis reports soluble guanylate cyclase activators

Galapagos and Gilead Sciences file transparency notification

New animal model designed to reproduce ischemia in head and neck surgery

3D-printed biomimetic tympanic membrane shows similar acoustic properties to human eardrum

Tissue-engineered cartilage shows promise for laryngotracheal reconstruction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...